MolecularMD Licenses DDR2 Markers for Assay Development | GenomeWeb

NEW YORK (GenomeWeb News) – MolecularMD today announced a licensing deal covering DDR2 mutations for lung cancer.

The Portland, Ore.-based company has obtained the rights to commercialize IP around the mutations for diagnostic, prognostic, and predictive uses. The IP is jointly owned by the Broad Institute and Dana-Farber Cancer Institute.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.